Merck & Co., Inc. (NYSE:MRK) Forecasted to Earn FY2022 Earnings of $7.24 Per Share – MarketBeat

This post was originally published on this site

Merck & Co., Inc. (NYSE:MRKGet Rating) – Research analysts at Cantor Fitzgerald increased their FY2022 earnings per share estimates for shares of Merck & Co., Inc. in a note issued to investors on Friday, April 29th. Cantor Fitzgerald analyst L. Chen now expects that the company will earn $7.24 per share for the year, up from their previous estimate of $7.12. Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its quarterly earnings results on Thursday, April 28th. The company reported $2.14 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.31. The business had revenue of $15.90 billion during the quarter, compared to analysts’ expectations of $14.64 billion. Merck & Co., Inc. had a net margin of 26.27% and a return on equity of 49.57%. The business’s revenue for the quarter was up 31.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.40 EPS.

Several other research firms also recently issued reports on MRK. Morgan Stanley decreased their price objective on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th. SVB Leerink decreased their target price on shares of Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating for the company in a research report on Thursday, April 21st. StockNews.com assumed coverage on shares of Merck & Co., Inc. in a research note on Thursday, March 31st. They set a “strong-buy” rating for the company. Mizuho began coverage on Merck & Co., Inc. in a report on Friday, April 1st. They set a “buy” rating and a $100.00 price target on the stock. Finally, Barclays lifted their price objective on Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a report on Tuesday, April 12th. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $90.69.

(Ad)

The global lithium market is projected to surge 500% due to a growing need for lithium-filled batteries. And one junior mining company in a renowned location in South America is in the right place at the right time to capitalize on this megatrend.

MRK stock opened at $88.69 on Monday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.02 and a current ratio of 1.27. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $91.40. The company has a fifty day moving average of $81.53 and a 200-day moving average of $80.12. The stock has a market capitalization of $224.19 billion, a PE ratio of 15.87, a price-to-earnings-growth ratio of 1.24 and a beta of 0.45.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Disciplined Investments LLC raised its stake in shares of Merck & Co., Inc. by 24.3% in the first quarter. Disciplined Investments LLC now owns 604 shares of the company’s stock worth $50,000 after acquiring an additional 118 shares during the last quarter. Pegasus Asset Management Inc. boosted its holdings in shares of Merck & Co., Inc. by 0.3% in the first quarter. Pegasus Asset Management Inc. now owns 34,987 shares of the company’s stock valued at $2,871,000 after buying an additional 119 shares during the period. Financial Management Professionals Inc. lifted its position in shares of Merck & Co., Inc. by 4.1% in the first quarter. Financial Management Professionals Inc. now owns 3,123 shares of the company’s stock worth $256,000 after purchasing an additional 123 shares in the last quarter. Sheets Smith Wealth Management lifted its position in shares of Merck & Co., Inc. by 0.5% in the fourth quarter. Sheets Smith Wealth Management now owns 24,741 shares of the company’s stock worth $1,896,000 after purchasing an additional 124 shares in the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. raised its position in Merck & Co., Inc. by 0.7% during the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 18,152 shares of the company’s stock worth $1,363,000 after acquiring an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 72.05% of the company’s stock.

About Merck & Co., Inc. (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Merck & Co., Inc. right now?

Before you consider Merck & Co., Inc., you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Merck & Co., Inc. wasn’t on the list.

While Merck & Co., Inc. currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

This post was originally published on *this site*